AMTN | Amelotin | Predicted secreted proteins
| ![](/images/36136/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/36136/81739_B_8_1_rna_selected_60x60.jpg) | Group enriched |
C12orf77 | Chromosome 12 open reading frame 77 | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
FCRL4 | Fc receptor-like 4 | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| ![](/images/54030/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/54030/123242_B_7_8_rna_selected_60x60.jpg) | Group enriched |
TMEM79 | Transmembrane protein 79 | Disease related genes Predicted membrane proteins
| | ![](/images/55214/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/55214/129352_B_8_3_rna_selected_60x60.jpg) | Group enriched |
BLK | B lymphoid tyrosine kinase | Cancer-related genes Disease related genes Enzymes Potential drug targets
| ![](/images/5093/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5093/14003_B_8_2_rna_selected_60x60.jpg) | Group enriched |
CD72 | CD72 molecule | CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2505/6522_A_7_1_rna_selected_60x60.jpg) | Group enriched |
CNR2 | Cannabinoid receptor 2 (macrophage) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/9719/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9719/29978_B_3_7_rna_selected_60x60.jpg) | Group enriched |
CSTB | Cystatin B (stefin B) | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Transporters
| | | ![](/images_static/rna_center.gif) | ![](/images/47320/103192_B_8_6_rna_selected_60x60.jpg) | Group enriched |
EPHX3 | Epoxide hydrolase 3 | Predicted secreted proteins
| ![](/images/12842/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12842/62761_B_7_4_rna_selected_60x60.jpg) | Group enriched |
FCRL2 | Fc receptor-like 2 | CD markers Predicted membrane proteins
| ![](/images/17619/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/17619/89010_B_8_6_rna_selected_60x60.jpg) | Group enriched |
HLA-DOB | Major histocompatibility complex, class II, DO beta | Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13846/32452_A_9_7_rna_selected_60x60.jpg) | Group enriched |
NLRP4 | NLR family, pyrin domain containing 4 | | ![](/images/42561/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42561/92428_B_2_4_rna_selected_60x60.jpg) | Group enriched |
RNF222 | Ring finger protein 222 | Predicted membrane proteins
| ![](/images/48916/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/48916/109915_B_9_1_rna_selected_60x60.jpg) | Group enriched |
TMEM40 | Transmembrane protein 40 | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/44165/102041_B_8_8_rna_selected_60x60.jpg) | Group enriched |
TNFRSF13C | Tumor necrosis factor receptor superfamily, member 13C | CD markers Disease related genes Predicted membrane proteins
| | ![](/images/8380/if_selected_60x60.jpg) | ![](/images/3246/ihc_cell_selected_60x60.jpg) | ![](/images/8380/19870_B_8_1_rna_selected_60x60.jpg) | Group enriched |
ZNF750 | Zinc finger protein 750 | Cancer-related genes Disease related genes
| | ![](/images/21573/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/21573/50402_B_8_6_rna_selected_60x60.jpg) | Group enriched |
ALOX12B | Arachidonate 12-lipoxygenase, 12R type | Disease related genes
| ![](/images/24002/ihc_selected_60x60.jpg) | ![](/images/24002/if_selected_60x60.jpg) | ![](/images/24002/ihc_cell_selected_60x60.jpg) | ![](/images/24002/52923_B_8_2_rna_selected_60x60.jpg) | Group enriched |
CXCR5 | Chemokine (C-X-C motif) receptor 5 | CD markers G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42432/123485_A_8_2_rna_selected_60x60.jpg) | Group enriched |
DSG3 | Desmoglein 3 | Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46864/148887_B_4_3_rna_selected_60x60.jpg) | Group enriched |
GJB5 | Gap junction protein, beta 5, 31.1kDa | Cancer-related genes Predicted membrane proteins
| ![](/images/38146/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38146/77306_B_9_1_rna_selected_60x60.jpg) | Group enriched |
HTR3A | 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
IL21 | Interleukin 21 | Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
IL24 | Interleukin 24 | Cancer-related genes Predicted secreted proteins
| ![](/images/8252/ihc_selected_60x60.jpg) | ![](/images/8252/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/8252/21432_B_7_7_rna_selected_60x60.jpg) | Group enriched |
IL36RN | Interleukin 36 receptor antagonist | Disease related genes
| ![](/images/34542/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/34542/70585_B_9_1_rna_selected_60x60.jpg) | Group enriched |
KLK6 | Kallikrein-related peptidase 6 | Cancer-related genes Enzymes Mitochondrial proteins Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
LCE3D | Late cornified envelope 3D | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
MEF2B | Myocyte enhancer factor 2B | Transcription factors
| ![](/images/4734/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/4734/13317_B_7_4_rna_selected_60x60.jpg) | Group enriched |
SDR16C5 | Short chain dehydrogenase/reductase family 16C, member 5 | Enzymes Predicted membrane proteins
| ![](/images/25224/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25224/53754_B_7_7_rna_selected_60x60.jpg) | Group enriched |
SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/15480/35524_A_4_6_rna_selected_60x60.jpg) | Group enriched |
SFN | Stratifin | Cancer-related genes Plasma proteins
| | | ![](/images/6268/ihc_cell_selected_60x60.jpg) | ![](/images/6268/17244_A_2_3_rna_selected_60x60.jpg) | Group enriched |
SPRR1B | Small proline-rich protein 1B | Cancer-related genes
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
TLR10 | Toll-like receptor 10 | CD markers Plasma proteins Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
VSIG10L | V-set and immunoglobulin domain containing 10 like | Predicted membrane proteins
| ![](/images/60453/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/60453/ihc_cell_selected_60x60.jpg) | ![](/images/60453/136022_B_8_3_rna_selected_60x60.jpg) | Group enriched |
BTLA | B and T lymphocyte associated | CD markers Predicted membrane proteins
| ![](/images/47211/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/47211/ihc_cell_selected_60x60.jpg) | ![](/images/47211/120195_A_6_7_rna_selected_60x60.jpg) | Group enriched |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/3796/11202_A_9_6_rna_selected_60x60.jpg) | Group enriched |
CLIC3 | Chloride intracellular channel 3 | Plasma proteins Transporters
| | | ![](/images_static/rna_center.gif) | ![](/images/5963/137904_B_8_5_rna_selected_60x60.jpg) | Group enriched |
CXCL13 | Chemokine (C-X-C motif) ligand 13 | Cancer-related genes Predicted secreted proteins
| ![](/images/52613/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/52613/126778_B_9_1_rna_selected_60x60.jpg) | Group enriched |
FAM159A | Family with sequence similarity 159, member A | Predicted membrane proteins
| ![](/images/30744/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/30744/101064_B_8_6_rna_selected_60x60.jpg) | Group enriched |
LTB | Lymphotoxin beta (TNF superfamily, member 3) | Cancer-related genes Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/48884/109189_B_8_4_rna_selected_60x60.jpg) | Group enriched |
PLA2G2D | Phospholipase A2, group IID | Enzymes Predicted secreted proteins RAS pathway related proteins
| ![](/images/46308/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46308/102936_B_9_1_rna_selected_60x60.jpg) | Group enriched |
PLA2G3 | Phospholipase A2, group III | Enzymes Predicted secreted proteins RAS pathway related proteins
| ![](/images/21016/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21016/51706_B_8_5_rna_selected_60x60.jpg) | Group enriched |
S100A7 | S100 calcium binding protein A7 | Cancer-related genes Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images/1453/ihc_cell_selected_60x60.jpg) | ![](/images/33766/101280_B_9_4_rna_selected_60x60.jpg) | Group enriched |
SELL | Selectin L | Cancer-related genes Candidate cardiovascular disease genes CD markers Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/2144/ihc_cell_selected_60x60.jpg) | ![](/images/2144/5972_A_7_7_rna_selected_60x60.jpg) | Group enriched |
SIT1 | Signaling threshold regulating transmembrane adaptor 1 | Predicted membrane proteins
| ![](/images/18506/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18506/41538_A_7_3_rna_selected_60x60.jpg) | Group enriched |
VSIG8 | V-set and immunoglobulin domain containing 8 | Predicted membrane proteins
| ![](/images/23219/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/23219/51010_B_9_3_rna_selected_60x60.jpg) | Group enriched |